StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Non-cash PP&E additions included in accounts payable by Year

Non-cash PP&E additions included in accounts payable and accrued liabilities ($M) ($M)

Moderna Non-cash PP&E additions included in accounts payable: $83M in FY2025, down 14.4% from a year earlier.

Latest, FY2025
83
Period ended Dec 31, 2025
Change on a year earlier
-14.4%
97 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Supplemental Cash Flow Information.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-cash PP&E additions included in accounts payable and accrued liabilities ($M) ($M)Year on yearSource
FY2025Dec 31, 202583-14.4%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 202497-25.4%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023130+80.6%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 202272-35.1%Form 10-K (filed 2025-02-21) ↗
FY2021Dec 31, 2021111+516.7%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 202018+260.0%Form 10-K (filed 2023-02-24) ↗
FY2019Dec 31, 20195-61.2%Form 10-K (filed 2022-02-25) ↗
FY2018Dec 31, 201812.9–Form 10-K (filed 2021-02-26) ↗

Cite this data

StockData. (2026). Moderna Non-cash PP&E additions included in accounts payable ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/capex-accrued-xbrl

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.